Introduction {#Sec1}
============

Bacterial vaginosis (BV) is one of the most common vaginal infections that affects women of reproductive age, with an estimated global prevalence of approximately \~ 20--60%, and involves substitution of the normal microbiota by anaerobic bacteria (Bautista et al. [@CR2]). The clinical symptomatology includes white or gray vaginal discharge and a "fishy" vaginal odor caused by the presence of volatile amines, such as cadaverine, putrescine, and trimethylamine; however, half of infected women present no symptoms (Kerubo et al. [@CR18]). The associated complications of BV include pelvic inflammatory disease, membrane rupture, low newborn birth weight in pregnant women (Hillier et al. [@CR16]), and an increase in susceptibility to the acquisition of sexually transmitted diseases, such as chlamydia, trichomonas, herpes virus, human immunodeficiency virus, and human papilloma virus (Buve et al. [@CR5]; Gillet et al. [@CR13]; Hay [@CR15]; Sweet [@CR34]; Thurman et al. [@CR35]). BV diagnosis is based on clinical symptomatology and cellular morphology observed in patients; among these, the Amsel (Amsel et al. [@CR1]) and Nugent (Nugent et al. [@CR26]) criteria are the most used.

*Gardnerella vaginalis*, the main etiological agent of BV, produces virulence factors associated with the invasion and colonization of the vaginal tract, such as vaginolysin, *biofilm* formation, prolidase, sialidase (SLD), among others, that are associated with the clinical outcomes observed in BV (Cauci et al. [@CR10]; Patterson et al. [@CR27]). The SLD is an enzyme that cleaves terminal sialic acid residues from human glycans (Lewis et al. [@CR22]) and is associated with tissue destruction, bacterial invasion, immune response evasion, and obtaining of nutrients related to bacterial growth (Cauci et al. [@CR8]; Cauci and Culhane [@CR6]; Lewis et al. [@CR21]). In addition to *G. vaginalis*, SLD is also produced by several BV-associated microorganisms, such as *Prevotella*, *Bacteroides*, and *Mobiluncus* (Briselden et al. [@CR4]; Schellenberg et al. [@CR31]; Smayevsky et al. [@CR33]).

Due to the importance of SLD during invasion and colonization of the vaginal tract, it has been proposed as a biomarker for BV diagnosis. Previous studies have shown that high levels of SLD are associated with BV cases, in comparison with the low levels found in healthy women (Briselden et al. [@CR4]; Cauci et al. [@CR7]; Marconi et al. [@CR23]). The most widely used techniques for SLD determination involve enzymatic evaluation using 2-(4-methylumbelliferyl)-d-N-acetylneuraminic acid (MUAN) as a substrate (Marconi et al. [@CR23]) or a rapid test termed BVBlue (Gryphus Diagnostics, LLC) (Myziuk et al. [@CR25]). In spite of this, the generation of new biological products to evaluate the roles of SLD during BV development and the standardization of new diagnostic techniques based on antigen--antibody reactions are needed, which could improve the diagnostic sensitivity and specificity. Taking into account all of the above-mentioned, the aim of this study was the production and characterization of a monoclonal antibody directed against *G. vaginalis* SLD.

Materials and methods {#Sec2}
=====================

*Gardnerella vaginalis* strain {#Sec3}
------------------------------

The *Gardnerella vaginalis* ATCC 14018 (ATCC® 14018™) strain was used, which was donated kindly by Graciella Castro-Escarpulli. The strain was grown in Columbia agar supplemented with 10% of human blood (from a healthy donor with previous consent), and the main morphological characteristic includes Gram-negative coccobacillus, negative oxidase and catalase, and positive hydrolysis of hippurate.

Peptide selection {#Sec4}
-----------------

For peptide design, we downloaded the reference sequence (WP_004132912.1) of *G. vaginalis* SLD from the NCBI protein database. The peptide was designed based on in silico analysis performed with the software ABCpred (Saha and Raghava [@CR30]) (<http://crdd.osdd.net/raghava/abcpred/>) and predicted antigenic peptides (Kolaskar and Tongaonkar [@CR20]) (<http://imed.med.ucm.es/Tools/antigenic.pl>). The peptide was selected according to its predicted characteristics of immunogenicity and antigenicity (necessary for immune response induction). The peptide was ten amino acids in length and included a portion of the amino terminal region of SLD. Peptide synthesis in multiantigenic peptide 8 (MAP8) format was performed by PepMic (<http://www.pepmic.com/>) and dissolved to a final concentration of 1 mg/mL and named SLD-MAP8.

Monoclonal antibody production {#Sec5}
------------------------------

Hybridomas were generated as previously described (Köhler and Milstein [@CR19]). Eight-week-old female BALB/c mice were immunized weekly with 30 μg of the SLD-MAP8 peptide using Freund's complete and incomplete adjuvants (Sigma-Aldrich Cat \# F5881 and Cat \# F5506). Hybrid generation was performed as previously described by our workgroup (Cortés-Sarabia et al. [@CR11]). Culture supernatant samples were monitored by indirect enzyme-linked immunosorbent assay (ELISA) using SLD-MAP8 peptide as antigen, and hybridomas secreting monoclonal antibodies (mAb) were subcloned twice by limiting dilution and maintained in DMEM cell culture medium (Sigma-Aldrich Cat \# D5796) with 10% fetal bovine serum (FBS, Gibco Cat \# 16000044) and antibiotics.

Polyclonal antibody production {#Sec6}
------------------------------

For a positive control, we employed polyclonal antibodies (pAbs) against the complete bacteria. We immunized a New Zealand rabbit with the complete inactivated bacteria using the *G. vaginalis* ATCC 14018 as an immunogen. The rabbit was immunized subcutaneously using complete (Life technologies Cat \# P1503) and incomplete Freund's (Sigma-Aldrich Cat \# F5506) adjuvants. The resultant hyperimmune serum was diluted 1:500 in all experiments performed in this work.

mAb and pAb purification {#Sec7}
------------------------

For quantitative analysis, mAbs and pAbs were purified from cell culture medium and rabbit serum, respectively, using protein A sepharose Cl-4B (GE Life Sciences Cat \# GE17-0963-03) following manufacturer's instructions. Purified IgG (mg/mL) concentrations were determined by measuring OD at 280 nm in a microplate reader (BioTek Epock).

Enzyme-linked immunosorbent assay {#Sec8}
---------------------------------

Evaluation of immune responses in the immunized mice, hybrid selection, mAb immunoglobulin class, SLD recognition in HeLa cells, antigens, and mAb titration was determined by indirect ELISA. Microtiter plates (Sigma-Aldrich Cat \# CLS3590) were coated with the antigen (SLD-MAP8, HeLa cell culture supernatant, or samples of *G. vaginalis*) by adding 100 μL of protein solution in a coating buffer (50 mM Na~2~CO~3~/NaCO~3~H, pH 9.6) and incubated overnight at 4 °C. Plates were blocked for 30 min at room temperature (RT) in 200 μL of 5% skimmed milk in PBS--Tween (0.05%) and then incubated with serum, culture supernatant or purified mAb for 2 h at 37 °C. After washing, the plates were incubated with 100 μL (dilution 1:2,000) of anti-mouse H + L (heavy + light) (Jackson ImmunoResearch Cat \# 115-035-003), anti-Mu (Jackson ImmunoResearch Cat \# 115-035-020), anti-gamma (Jackson ImmunoResearch Cat \# 115-035-164), anti-IgG1 (Cat \# SAB3701169), anti-IgG2a (Sigma-Aldrich Cat \# SAB3701178), anti-IgG2b (Sigma-Aldrich Cat \# 3701185), or anti-IgG3 (Sigma-Aldrich Cat \# SAB3701192) coupled to HRP (horseradish peroxidase) (except IgG1 for which we used protein A coupled to HRP for detection), diluted in 0.05% PBS--Tween and incubated for 2 h at 37 °C. The enzymatic reaction was developed using O-phenylenediamine dyhydrochloride (Sigma-Aldrich Cat \# P1526) and terminated with 2 N H~2~SO~4~. The optical density was measured at 492 nm in a microplate reader (Tecan Sunrise).

Protein precipitation from *G. vaginalis* culture supernatant {#Sec9}
-------------------------------------------------------------

We added 1 mL of acetone to 500 μL of *G. vaginalis* culture medium, and the solution was mixed and incubated for 1 h at − 20 °C. Next, the tube was centrifuged for 15 min at 14,000 rpm, and the supernatant was discarded. The obtained pellet was dried at room temperature and resuspended in 30 μL of PBS.

Western and dot blots {#Sec10}
---------------------

For Western blotting, 20 μg of the total protein lysate from *G. vaginalis* ATCC 14018 strain was denatured in a loading buffer at 98 °C for 10 min (Biorad Cat \# 1610747), then separated by 12% SDS-PAGE, and transferred to a nitrocellulose membrane (Biorad Cat \# 1620115). Membranes were blocked with 5% skim milk in 0.05% PBS--Tween for 40 min at RT with shaking. After washing, the membrane was incubated with mAbs at a final concentration of 10 μg/mL at room temperature and with constant agitation for 2 h, followed by incubation with HRP-conjugated anti-mouse IgG antibody (dilution 1:2000), or anti-rabbit IgG antibody (dilution 1:4000) in 0.05% PBS--Tween, for 2 h. Immunoreactivity was developed with 3-3′-diaminobenzidine (DAB, Sigma-Aldrich Cat \# D8001). Dot blots similarly used total protein lysates, complete bacteria, or culture supernatant immobilized on nitrocellulose membranes.

Isolation and culture of *G. vaginalis* {#Sec11}
---------------------------------------

Isolation of *G. vaginalis* from clinical samples was performed on Columbia agar supplemented with 10% human blood and the selective agent SR119RE (OXOID Cat \# 1441974). Vaginal swab samples were inoculated and incubated at 37 °C under a 5% CO~2~ atmosphere for 24 h. Microbial identification was performed by Gram staining and catalase and oxidase negative reactions. Isolated bacteria were inoculated in thioglycollate broth and incubated at 37 °C in 5% CO~2~ atmosphere for 24 h. Broth cultures were used for biotyping tests and dot blot experiments.

Biotyping {#Sec12}
---------

Biotyping was performed based on the classification scheme proposed by Piot et al. ([@CR28]). Hippurate hydrolysis: 100 μL of the broth culture was inoculated into an aliquot containing 400 μL of 1% sodium hippurate reagent (Sigma-Aldrich Cat \# H9380), which was incubated at 37 °C for 2 h and then 200 μl of ninhydrin (Sigma-Aldrich Cat \# 151173) was added and the solution homogenized. The test was interpreted as positive when the medium turned purple, indicating the presence of glycine in the mixture as a result of hippurate hydrolysis, and negative when the reagent did not change color. β-Galactosidase activity was determined using 100 μL of the broth culture inoculated into an aliquot of the 2-nitrophenyl-β-D-galactopyranoside reagent (Sigma-Aldrich Cat \# N1127) and incubated at 37 °C for 24 h. The test was interpreted as positive when the reagent in the tube turned yellow, indicating the presence of O-nitro phenol formed by the action of β-galactosidase, which indicates that the bacteria had metabolized lactose, and the test was interpreted as negative when the reagent did not change color. The production of lipase was evaluated according to the method described by Moncla and Pryke ([@CR24]). Bacteria were inoculated on egg yolk agar and incubated at 37 °C for 24 h, and the presence of an iridescent halo surrounding the colonies was considered as a positive result, and the absence of this halo as negative.

For the analysis of SLD expression in the clinical samples using dot blots, we used ImageJ software (Schneider et al. [@CR32]) to perform a qualitative analyses of each blot, and considered the IntDent (integrated density) of each sample as crude data. Background subtraction was performed for each sample for data homogenization using a negative control.

*G. vaginalis* culture and growth kinetics {#Sec13}
------------------------------------------

*G. vaginalis* ATCC 14018 strain was cultured anaerobically at 37 °C in 5% CO~2~ for 24 h in Trypticasein Soy Agar (TSA) (Becton, Dickinson and Company, Sparks MD, USA). To establish the growth kinetics of *G. vaginalis*, a bacterial colony was inoculated into 5 mL of brain heart infusion broth (BHI) (Becton, Dickinson and Company, Sparks MD, USA), and incubated at 37 °C with 5% of CO~2~ and 180 rpm agitation, overnight. Next, OD was adjusted to 0.2 (equivalent to 15 × 10^6^ CFU/mL) and finally, 50 mL of BHI broth was inoculated in triplicate with 10 mL of the OD-adjusted bacteria. Bacterial growth was monitored at 0.5, 1, 2, 4, 8, 10, 12, 24, 36, 48, and 72 h. Absorbance was measured at 595 nm in a spectrophotometer (Bio Rad iMark), and non-inoculated broth was used as a negative control.

SLD production during growth of *G. vaginalis* {#Sec14}
----------------------------------------------

SLD production in bacterial cultures was evaluated using mAb and an indirect ELISA method. For this, the bacteria (1:200 dilution), culture supernatants, and complete bacteria of each monitored time point (0.5 to 72 h) were fixed in 96-well plates for 2 h at 37 °C and then blocked with 5% skim milk (BD Difco Cat \# 232100) in PBS--Tween during 30 min at 37 °C. Anti-SLD mAb was used at 10 μg/mL, and anti-mouse HRP-coupled IgG diluted 1:2000 in PBS--Tween was used as a secondary antibody. The reaction was developed using O-phenylenediamine dyhydrochloride (Sigma-Aldrich Cat \# P9029) and stopped with 2 N sulfuric acid.

HeLa cell culture and infection with *G. vaginalis* {#Sec15}
---------------------------------------------------

HeLa cells (derived from a woman with cervical adenocarcinoma and HPV 18 infection) were grown on Petri dishes (Corning-Costar) in growth medium composed of DMEM/F-12 (Sigma-Aldrich Cat \# D9785) supplemented with 10% fetal bovine serum (Sigma-Aldrich Cat \# F2442), 100 U/mL penicillin, 100 μg/mL streptomycin (Gibco Cat \# 15140122), and 1 μg/mL amphotericin B (Thermo Fisher Cat \# 15290018). HeLa cells were grown under a 5% CO~2~ atmosphere at 37 °C, and 24 h before infection with *G. vaginalis*, cells were cultured in serum-free medium without antibiotics. On the next day, HeLa cells were infected for 2 and 4 h, with the following multiplicities of infection (MOI); 1:1 and 20:1 bacterium per cell (15 × 10^6^ CFU/mL) under 5% CO~2~ and at 37 °C. After infection, culture supernatants were collected and used for indirect ELISAs and dot blots.

Results {#Sec16}
=======

First, we selected a peptide based on the results of in silico analysis considering the localization (N-terminal), immunogenicity, and antigenicity. The obtained SLD-MAP8 synthetic peptide was used for the immunization of five BALB/c mice. We performed immune response evaluations in all of the immunized mice. According to the results, the mouse with the highest titer was selected for hybridoma production (Fig. [1a](#Fig1){ref-type="fig"}). Subsequently, the mouse was sacrificed and spleen was used for fusion with myeloma cells for hybridoma generation (Fig. [1c and d](#Fig1){ref-type="fig"}). After fusion, seven different anti-SLD antibody-producing clones were selected; six of these produced IgM antibodies, while clone 1H12 produced essentially IgG antibodies (Fig. [1b](#Fig1){ref-type="fig"}). Clone 1H12 was selected and named as anti-SLD mAb. This clone was grown in DMEM, and anti-SLD mAb was obtained and used for the following experiments.Fig. 1Immune response evaluation and anti-SLD clones. (**a**) Immune response evaluation in selected mice. Indirect ELISA using as primary antibody the collected serum during the immunization process. As a secondary antibody, we used an anti-H + L antibody. (**b**) Evaluation of clones obtained after fusion. Indirect ELISA using as primary antibody the culture supernatant of the evaluated clones in order to determine the immunoglobulin class produced by each clone. We used specific antibodies against the mu and gamma chains. (**c**) and (**d**) Representative images of the hybridomas produced

Next, the immunoglobulin class and subclass using specific antibodies were determined. The IgG antibodies produced by clone 1H12 belonged to the IgG1 subclass (Fig. [2a](#Fig2){ref-type="fig"}), and the purified antibody only showed the heavy and light chains of the immunoglobulin (Fig. [2b](#Fig2){ref-type="fig"}). Further characterization included the determination of optimal concentration of antibody and antigen using the SLD-MAP8 synthetic peptide. The optimal antibody concentration was 10 μg/mL, and the antigen concentration to be detected was \~ 0.16 μg/mL (Fig. [2c and d](#Fig2){ref-type="fig"}).Fig. 2Anti-SLD mAb. (**a**) Immunoglobulin class and subclass produced by the 1H12 clone. As primary antibody, we used the culture supernatant of clone 1H12, mouse hyperimmune serum (C+), and no hyperimmune serum (C−). As secondary antibodies, we used specific antibodies against different classes (IgM and IgG) and subclasses (IgG1, IgG2a, IgG2b, and IgG3). (**b**) Anti-SLD mAb purification evaluation. 12% SDS-PAGE and Coomassie blue staining. MWM, molecular weight marker; HC, heavy chain; LC, light chain. (**c**) and (**d**) Antibody and antigen titration. Indirect ELISA using decreasing concentrations of antigen and purified antibody by double dilution. As primary antibody, we used purified 1H12 antibody, and as secondary antibody, an anti-H + L antibody was used

Next, the specificity of the anti-SLD mAb was evaluated in *G. vaginalis* ATCC 14018 strain, to determine if the antibody could recognize the complete, intact form of SLD. By Western blot, it was determined that the anti-SLD mAb recognized the complete protein in denatured form, with a single band of approximately 90 kDa detected, which correlated with the predicted molecular weight of SLD (Fig. [3a](#Fig3){ref-type="fig"}). After this, we evaluated by dot blot SLD recognition in the complete bacteria, culture supernatant, and total protein extract using *G. vaginalis* ATCC 14018 strain and four clinical isolates belonging to the biotypes 1, 2, 5, and 6. Interestingly, the anti-SLD mAb not only showed high levels of recognition in the complete bacteria and protein extract but also detected SLD in the culture media of clinical isolates (Fig. [3b](#Fig3){ref-type="fig"}). To corroborate previously obtained results, we performed evaluations by indirect ELISA using total protein extract and culture supernatant, and the results were similar (Fig. [3c and d](#Fig3){ref-type="fig"}).Fig. 3Preliminary characterization of 1H12 anti-SLD mAb. (**a**) and (**b**) Western blot and dot blot analyses. We used total lysates, complete bacteria, or culture supernatants of *G. vaginalis* ATCC 14018 strain and clinical isolates of biotypes 1, 2, 5, and 6 as antigens. (**c**) and (**d**) Detection of SLD in the ATCC 14018 strain and clinically isolated biotypes of *G. vaginalis*. Indirect ELISA using protein total extract and proteins precipitated from the culture supernatants to evaluate antibody recognition. In all experiments, 1H12 anti-SLD mAb, C+ is polyclonal antibody against *G. vaginalis* and in C− primary antibody was omitted. As secondary antibody, an anti-H + L antibody was used

We speculated whether the anti-SLD mAb could be used to predict in a semi-qualitative way the amount of SLD produced by *G. vaginalis* during the different phases of bacterial growth, considering that this protein is a primary metabolite. For this, the bacteria were cultured for 72 h and the samples were collected at different times (Fig. [4a](#Fig4){ref-type="fig"}). We observed that after the first 30 min, the bacteria begin to produce SLD, and the increase was proportional to the growth phase (Fig. [4b](#Fig4){ref-type="fig"}). Next, SLD production was evaluated by dot blot in 67 clinical isolates of *G. vaginalis* from women with normal microbiota (NM; n = 45) and bacterial vaginosis (BV; n = 22) belonging to four (1, 2, 5, and 6) of the eight different *G. vaginalis* biotypes (Table [1](#Tab1){ref-type="table"}). Results showed that the amount of SLD produced varied between isolates, and even between complete bacteria and supernatants (Fig. [5a](#Fig5){ref-type="fig"}). Using the previous blots, we analyzed in a semi-qualitative way the amount of SLD in the samples isolated from women with NM and BV, observing similar results in both groups (Fig. [5b](#Fig5){ref-type="fig"}). In addition, samples were separated according to biotype; 1 (n = 15), 2 (n = 6), 5 (n = 11), and 6 (n = 35) (Table [1](#Tab1){ref-type="table"}), and we observed that biotypes 2 and 5 secreted less SLD in comparison to biotypes 1 and 6 (Fig. [5c](#Fig5){ref-type="fig"}).Fig. 4Evaluation of SLD recognition during growth of *G. vaginalis* (**a**) Growth curve of *G. vaginalis*. We used as culture medium brain heart infusion, and optical density was determined at 600 nm during 0.5, 1, 2, 4, 8, 10, 12, 24, 36, 48, and 72 h. (**b**) Detection of SLD during the growth of *G. vaginalis*. Indirect ELISA for qualitative evaluation of the SLD present in samples of complete bacterial culture (bacteria + culture supernatant), culture supernatant, or bacteria only. As primary antibody, we used the 1H12 anti-SLD antibody and as secondary antibody, we used an anti-H + L antibodyTable 1.Clinical isolates used in this studyDiagnosticBiotypeNormal microbiota n (%)Bacterial vaginosis n (%)Total113 (28.9)2 (9.1)15 (22.4)22 (4.4)4 (18.2)6 (9.0)511 (24.5)0 (0.0)11 (16.4)619 (42.2)16 (72.7)35 (52.2)Total46 (100)22 (100)67 (100)Fig. 5SLD recognition in clinical samples. (**a**) and (**b**) Dot blot results of SLD evaluation in the complete bacteria and culture supernatants. Each dot is a different clinical sample, and we used the same sample in the same position in the complete bacteria and culture supernatants. Dot blots were performed as previously described. Negative controls: E8--9, H7--9; positive controls: E10, H10. (**c**) and (**d**) Densitometric analysis of the dot blots. The analysis was carried out using ImageJ software

In addition, we investigated if the anti-SLD mAb could be used for the specific detection of *G. vaginalis* in HeLa cells infected and uninfected with the bacteria in the same way as in the clinical samples. Thus, we infected HeLa cells with *G. vaginalis* ATCC 14018 strain with a MOI of 1 and 20 for 2 and 4 h and evaluated SLD in culture supernatants by ELISA and dot blot (Fig. [6a](#Fig6){ref-type="fig"}). By indirect ELISA, we did not observe recognition of SLD by anti-SLD mAb in non-infected cells, while in cells infected at MOI 1 and 20, high recognition was observed for both infection periods (2 and 4 h) (Fig. [6b](#Fig6){ref-type="fig"}), and similar results were observed with dot blots (Fig. [6c](#Fig6){ref-type="fig"}).Fig. 6Evaluation of SLD in HeLa cells infected with *G. vaginalis* (**a**) Representative images of HeLa cells infected with *G. vaginalis.* Cells were infected with a MOI (multiplicity of infection) of 1 and 20 over 2 and 4 h. (**b**) Indirect ELISA and (**c**) Dot blot evaluation of SLD in infected HeLa cells. HPI, hours post-infection. The primary antibody used was 1H12, and as a secondary antibody, we used an anti-H + L antibody

Discussion {#Sec17}
==========

BV is the main vaginal infection in woman of reproductive ages and has been associated with clinical complications that affect the quality of life (Hay [@CR15]). The etiology of BV involves several genera of anaerobic bacteria, among them *Gardnerella*, *Bacteroides*, and *Mobiluncus*, which, according to previous reports, present a common virulence factor, the SLD enzyme (Briselden et al. [@CR4]; Schellenberg et al. [@CR31]; Smayevsky et al. [@CR33]). SLD plays important roles in obtaining nutrients, colonization, and host immune response evasion (Harvey et al. [@CR14]; Lewis et al. [@CR21]; Marconi et al. [@CR23]). Given the importance of SLD in the development of BV, the production and characterization of a monoclonal antibody against this enzyme are necessary, which were the main objectives of this work.

Hybridomas were obtained by the immunization of mice with a synthetic multiantigenic peptide (selected from the SLD primary structure) with an eight-chain (MAP8) format. This peptide stimulated the production of antibodies that were detected in the blood of immunized mice (Fig. [1a](#Fig1){ref-type="fig"}). The MAP8 format increases the peptide size and structural complexity and allows increased antigenicity during immunization; it is also commonly used as diagnostic reagent and vaccine (Joshi et al. [@CR17]). After fusion evaluation, seven anti-SLD producing clones were obtained (Fig. [1b](#Fig1){ref-type="fig"}). We selected clone 1H12 due to in vitro growth and the type of immunoglobulin class produced. IgG antibodies are commonly used in diagnostic techniques due to their structural stability and functionality after extended storage times. Also, the IgG1 subclass is the most common immunoglobulin (Vidarsson et al. [@CR37]).

As the antibody was produced using a synthetic peptide in MAP8 format, characterization was focused on demonstrating recognition of the complete protein. We observed that the anti-SLD mAb recognized SLD under native (indirect ELISA and dot blot) and denaturing (Western blot) conditions. In Western blot, a single of band of \~ 90 kDa was detected, which was a preliminary indicator of the antibody specificity (Fig. [3](#Fig3){ref-type="fig"}). All of the preliminary data supported the hypothesis that the chosen sequence exposes an epitope that allows SLD identification under several conditions necessary for immunoassays. Another interesting fact is that the anti-SLD mAb showed high recognition in samples of complete bacteria and culture supernatant, which could mean that during the secretion process, SLD first is anchored to the membrane (Rodriguez-Walker and Daniotti [@CR29]), and after being secreted, commences its function of obtaining nutrients (Lewis et al. [@CR22]). In addition, antibody recognition of the ATCC 14018 strain and the clinical isolates provides evidence regarding the extent of conservation of the selected epitope among the different *G. vaginalis* biotypes (Figs. [3](#Fig3){ref-type="fig"} and [5](#Fig5){ref-type="fig"}).

We investigated SLD production during bacterial growth and in infected HeLa cells. Our results showed that the synthesis of SLD commences during the first 30 min of culture and that protein levels were correlated with the bacteria amount and duration of infection. Previous reports revealed that SLD is considered to be a primary and secondary metabolite of *G. vaginalis*, and its production starts during the first minutes of bacterial growth and gradually increases (Cauci et al. [@CR9]). In the preliminary analysis of SLD production in the clinical biotypes, we did not find any difference between SLD production among the biotypes, or its association with BV. One possible explanation is that the stress of cell culture could induce the production of SLD; complementary studies need to be performed to prove this hypothesis.

Finally, SLD is released by several microorganisms associated with BV besides *G. vaginalis*, and its activity is increased in cases of BV (Briselden et al. [@CR4]; Cauci et al. [@CR7]; Ferreira et al. [@CR12]; Marconi et al. [@CR23]), which supports the use of SLD as a potential diagnostic biomarker. However, there is a need for additional complementary experiments to evaluate mAb cross-reactivity with other microorganisms that colonize mucosa, identify antibody affinity, and complete validation of the produced antibody according to established protocols (Bordeaux et al. [@CR3]; Uhlen et al. [@CR36]). Preliminary data encourage us to perform new studies to evaluate the potential clinical use of the produced mAb in the diagnosis of BV in clinical samples.

In conclusion, our data showed that the anti-SLD mAb detects SLD in complete bacteria, protein extracts, bacterial culture supernatants, and infected HeLa cells. The anti-SLD mAb also could be used in the standardization of new techniques for the detection of SLD in clinical samples from women with and without BV to improve early diagnosis and avoid associated complications.
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